Suppr超能文献

三种替代血浆纤维蛋白原检测方法与 von Clauss 检测法在预测心血管疾病和全因死亡率方面的直接比较:苏格兰心脏健康扩展队列研究。

Direct comparisons of three alternative plasma fibrinogen assays with the von Clauss assay in prediction of cardiovascular disease and all-causes mortality: the Scottish Heart Health Extended Cohort.

机构信息

Epidemiology, The George Institute, Sydney, NSW, Australia.

出版信息

Br J Haematol. 2013 Aug;162(3):392-9. doi: 10.1111/bjh.12389. Epub 2013 May 24.

Abstract

There is strong evidence from meta-analyses of prospective epidemiological studies that increasing plasma fibrinogen levels are associated with an increasing risk of cardiovascular disease (CVD) and all-cause mortality. However, there are few published direct comparisons of the several different available fibrinogen assays in association with CVD or mortality. We therefore prospectively compared the standardized von Clauss assay of clottable fibrinogen with three other assays: prothrombin time (PT)-derived clottable fibrinogen, immunonephelometric fibrinogen, and heat precipitable fibrinogen in the Scottish Heart Health Extended Cohort. Hazard ratios (HRs) for a standard deviation increase in fibrinogen for risk of CVD, adjusted for age and sex, were 1.17 (95% confidence interval [CI] 1.14; 1.21) for the von Clauss assay; 1.19 (1.06; 1.33) for the heat precipitation assay; 1.16 (1.01; 1.35) for the PT-derived assay; and 1.28 (1.10; 1.51) for the immunonephelometric assay. HRs for all-cause mortality were 1.21 (1.18; 1.24); 1.13 (1.01; 1.26), 1.17 (1.00; 1.37) and 1.17 (0.99; 1.39), respectively. No significant differences were observed between the assays in such comparisons. We therefore conclude that the choice between plasma fibrinogen assays in routine clinical haematology and biochemistry laboratories should depend on practical factors, and not on expected differences in the strength of associations.

摘要

有强有力的证据表明,通过荟萃分析前瞻性流行病学研究,血浆纤维蛋白原水平升高与心血管疾病(CVD)和全因死亡率的风险增加有关。然而,目前关于几种不同纤维蛋白原检测方法与 CVD 或死亡率的直接比较研究较少。因此,我们前瞻性地比较了标准化的 von Clauss 纤维蛋白原检测法与其他三种检测方法:凝血酶原时间(PT)衍生的可凝固纤维蛋白原、免疫比浊法纤维蛋白原和热沉淀纤维蛋白原,在苏格兰心脏健康扩展队列中。校正年龄和性别后,纤维蛋白原标准偏差增加与 CVD 风险的风险比(HR)分别为 von Clauss 检测法 1.17(95%置信区间 [CI] 1.14;1.21);热沉淀检测法 1.19(1.06;1.33);PT 衍生检测法 1.16(1.01;1.35);免疫比浊法检测法 1.28(1.10;1.51)。全因死亡率的 HR 分别为 1.21(1.18;1.24)、1.13(1.01;1.26)、1.17(1.00;1.37)和 1.17(0.99;1.39)。在这些比较中,各检测方法之间未观察到显著差异。因此,我们得出结论,在常规临床血液学和生物化学实验室中选择血浆纤维蛋白原检测方法应取决于实际因素,而不是关联强度的预期差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验